Nicholas Grund
Corporate Officer/Principal bei AKEBIA THERAPEUTICS, INC.
Vermögen: 403 389 $ am 30.04.2024
Aktive Positionen von Nicholas Grund
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AKEBIA THERAPEUTICS, INC. | Corporate Officer/Principal | 09.01.2024 | - |
Karriereverlauf von Nicholas Grund
Ehemalige bekannte Positionen von Nicholas Grund
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Transplant Genomics, Inc.
Transplant Genomics, Inc. BiotechnologyHealth Technology Transplant Genomics, Inc. operates as a molecular diagnostic company. It develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes and enable optimization of therapy. The company was founded by Daniel Salomon in 2013 and is headquartered in Mansfield, MA. | Corporate Officer/Principal | 01.01.2021 | 01.11.2022 |
AMAG PHARMACEUTICALS, INC. | Corporate Officer/Principal | 04.01.2016 | 29.03.2019 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2007 | 01.12.2015 |
Bayer Diagnostics Corp. | Corporate Officer/Principal | 01.01.1995 | 01.01.2002 |
Ausbildung von Nicholas Grund
Northeastern University | Masters Business Admin |
University of Massachusetts | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Corporate Officer/Principal | 5 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AKEBIA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Bayer Diagnostics Corp. | Health Technology |
Transplant Genomics, Inc.
Transplant Genomics, Inc. BiotechnologyHealth Technology Transplant Genomics, Inc. operates as a molecular diagnostic company. It develops molecular diagnostic tests that detect early signs of graft injury, differentiate among actionable causes and enable optimization of therapy. The company was founded by Daniel Salomon in 2013 and is headquartered in Mansfield, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Nicholas Grund
- Erfahrung